header logo image


Page 224«..1020..223224225226..230240..»

Eve & Co Announces Financial Results for the Year Ended December 31, 2020

May 2nd, 2021 1:53 am

STRATHROY, Ontario, April 30, 2021 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce its financial results for the year ended December 31, 2020. The financial statements and management discussion and analysis for such period are available on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com and on Eve & Co's website at www.evecannabis.ca.

Read more here:
Eve & Co Announces Financial Results for the Year Ended December 31, 2020

Read More...

Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

May 2nd, 2021 1:53 am

Basel, May 1, 2021 — Novartis today announced positive one-year results of the Phase III KESTREL and KITE* studies, evaluating the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of non-inferiority in change in best corrected visual acuity (BCVA) from baseline for Beovu 6 mg versus aflibercept 2 mg at year one1. In KESTREL, patients on Beovu 6 mg gained a mean of 9.2 letters versus 10.5 letters for patients on aflibercept 2 mg1. In KITE, patients on Beovu 6 mg gained a mean of 10.6 letters versus 9.4 letters for patients on aflibercept 2 mg1. These results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.

Read the rest here:
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

Read More...

Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases…

May 2nd, 2021 1:53 am

Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4 Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4

Go here to see the original:
Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases...

Read More...

Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in…

May 2nd, 2021 1:53 am

PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting, being held on May 1-5.

Read more:
Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in...

Read More...

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage…

May 2nd, 2021 1:53 am

SOUTH SAN FRANCISCO, Calif., May 01, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced final results from Phase 1 and Phase 1b studies of its small molecule LRRK2 inhibitor, BIIB122/DNL151, which is being developed in collaboration with Biogen as a potential treatment of Parkinson’s disease. Safety and biomarker goals were met in both studies, supporting plans to advance BIIB122/DNL151 into late-stage clinical development in Parkinson’s disease by year-end 2021. The results will be presented at the International Association of Parkinsonism and Related Disorders Virtual Congress, being held May 1-4.

Read the original:
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage...

Read More...

Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in…

May 2nd, 2021 1:53 am

-- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed ---- 60% of patients injection free beyond 1 year following 2 x 10^11 single dose --

Read the original post:
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in...

Read More...

COVID-19 vaccines may not offer complete protection for people with compromised immune systems – ABC News

May 2nd, 2021 1:53 am

If you have a weakened immune system, the COVID-19 vaccines may have a reduced effectiveness for you. Experts say it's still very important for you and those around you to get vaccinated, but it may be necessary for those with compromised immune systems to take extra precautions after vaccination.

"We are aware that this population may not have the same beneficial response to vaccines that we see in others who are not immunosuppressed," Dr. Linda Finn, the director of hematology and bone marrow transplant at Ochsner Health, told ABC News. "We do still recommend the vaccines, any benefit they can borrow from it, but still follow other precautions very closely."

Although clinical trials found vaccines were highly effective in preventing symptomatic or severe COVID-19 infections, these trials largely excluded people who were immunocompromised.

That means these estimates may not apply to people with weakened immune systems, such as people with cancer or HIV.

It can also include people who are taking medications that weaken the immune system to manage medical conditions, like those with autoimmune conditions or who have had transplants. Approximately 3% of the U.S. population is immunocompromised, according to the Centers for Disease Control and Preventions National Health Interview Survey.

Recent studies suggest that some of the conditions or treatments for the conditions interfere with the body's ability to create antibodies that help protect against COVID-19 after vaccination.

"It's been disheartening, obviously, for the patients to begin to realize, 'Hmm, this number of 95% effective that you hear about in the mRNA vaccine trials does not necessarily apply to me,'" Dr. Ghady Haidar, a transplant infectious disease physician at the University of Pittsburgh Medical Center, told ABC News.

A medical worker administer the Jansen (Johnson and Johnson) Covid-19 vaccine to the public at a FEMA run mobile Covid-19 Vaccination clinic at Biddeford High School in Bidderford, Maine on April 26, 2021.

Normally a fully vaccinated person will produce COVID-19 antibodies, and those antibodies should show up on an antibody test. But some fully vaccinated people who are immunocompromised have been surprised to learn they're not producing enough antibodies to test positive on an antibody test.

In one study, just over half of patients with blood, bone marrow, and lymph node cancer had antibodies; in another, less than 40% of patients with the blood cancer CLL (chronic lymphocytic leukemia) had an antibody response.

It is not yet known why this may be happening. The reduced antibody response may be due to these patients' underlying diseases, the medications they are taking, or both. Additional studies are needed to figure this out.

Experts think the vaccine should provide some protection for those who are immunocompromised, but they are still working to determine how much.

Researchers noted that antibody monitoring only measures one way the body responds to infections and there are other ways your immune system might be protecting you that wouldn't show up on an antibody test, including T-cell response, which is more challenging to test for than antibodies.

"It's definitely possible that there was still immunity built up even if the test didn't acknowledge the presence of antibodies," said Dr. John Brownstein, an epidemiologist at Boston Children's Hospital and an ABC News contributor.

"We need to develop protocols for those who are antibody negative [after vaccination]," said Dr. Mounzer Agha, a hematologist at UPMC Hillman Cancer Center and the lead author of the first study mentioned above. "The reason for testing right now would be to tell patients that they may still be vulnerable and should continue to exercise caution."

"No matter what the antibody results are, that should be the message: Continue living life safely, masking and social distancing," Haidar added.

Experts agreed that a patient's immunocompromised status is not a reason to not get a COVID-19 vaccine and that it is not only safe to do so, but very important, as they could be more at risk of becoming severely ill from COVID.

"Unless there is an absolute contraindication, which may be some allergy guidelines to avoid reactions to prior vaccines, I haven't had a patient yet that I have not advised to get the vaccine if they can," said Finn.

People with weakened immune systems will also be protected if everyone in their surrounding community is fully vaccinated, which is a concept known as "herd immunity."

Finn is recommending people get vaccinated with "what is available in their area." There is no data that favors one type or brand of vaccination over another for people with these conditions.

Experts agree that more data is needed to understand when to give vaccines to people undergoing chemotherapy, and those taking immunosuppressive medications. For now, the CDC recommends that patients starting immunosuppressive therapies get vaccinated at least two weeks prior.

Finn said it's a bit more nuanced and depends on your personal treatment plan. While she generally agrees with following the CDC's recommendations, this isn't always possible, as some patients need tighter treatment schedules with more individualized discussions.

Patients should talk to their doctors about what to do with their immunosuppressive medications and the timing of vaccination, as it may not be safe to space out, pause, or stop their medications.

Even after vaccination, people who are immunocompromised should continue to take extra precautions to avoid getting COVID-19.

"I think this patient population should expect to be following pretty broad COVID precaution guidelines for a long time," said Finn.

Some people may not know if they have a condition or take a medication that may impact the effectiveness of the vaccine. This is another reason continuing to mitigate risk with masking in crowded or indoor locations is recommended.

Haidar notes that immunocompromised people can also "encourage others around them to live their lives safely, including getting vaccinated," a step which benefits the individual and those around them.

Amanda Benarroch, M.D., is a psychiatry resident at Mayo Clinic in Rochester, Minnesota. Olivia Davies is a fourth-year student at the Medical College of Wisconsin who will be starting her residency at Massachusetts General Hospital this summer. Karine Tawagi, M.D., is a hematology and oncology fellow at Ochsner Medical Center in New Orleans. All three are contributors to the ABC News Medical Unit.

Follow this link:
COVID-19 vaccines may not offer complete protection for people with compromised immune systems - ABC News

Read More...

Experts say healthy diet and light exercise may boost immune response to the COVID-19 vaccine – WDJT

May 2nd, 2021 1:53 am

'); if(!WVM.IS_STREAMING){ $videoEl.append('' + '' + ''); } setTimeout(function(){ $('.mute-overlay').on('touchstart click', function(e){ if(e.handled === false) return; e.stopPropagation(); e.preventDefault(); e.handled = true; player.muted(false); //console.log("volumee " + WVM.activePlayer.volume()); $(this).hide(); $(this).css('display', 'none'); var currentTime = player.currentTime(); if(currentTime 0){ if(deviceName == 'desktop'){ WVM.VIDEO_TOP = $('#media-container-' + videoId).offset().top; }else{ WVM.VIDEO_TOP = $('#media-container-' + videoId).offset().top - $('.next-dropdown-accordion').height(); } if(deviceName == 'desktop'){ WVM.VIDEO_HEIGHT = $('#html5-video-' + videoId).outerHeight(); }else{ WVM.VIDEO_HEIGHT = $('#html5-video-' + videoId).outerHeight(); } WVM.CONTAINER_HEIGHT = $('#media-container-' + videoId).height(); //console.log("container height: " + WVM.CONTAINER_HEIGHT); $(window).on( "resize", function() { if(deviceName == 'desktop'){ WVM.VIDEO_TOP = $('#media-container-' + videoId).offset().top; }else{ WVM.VIDEO_TOP = $('#media-container-' + videoId).offset().top - $('.next-dropdown-accordion').height(); } if(deviceName == 'desktop'){ WVM.VIDEO_HEIGHT = $('#html5-video-' + videoId).outerHeight(); }else{ WVM.VIDEO_HEIGHT = $('#html5-video-' + videoId).outerHeight(); } WVM.CONTAINER_HEIGHT = $('#media-container-' + videoId).height(); console.log("container height: " + WVM.CONTAINER_HEIGHT); }); //console.log("VIDEOTOP: " + WVM.VIDEO_TOP); //console.log("VIDEOHEIGHT: " + WVM.VIDEO_HEIGHT); $(window).on( "scroll", function() { if(!WVM.IS_FLOATING){ if(deviceName == 'desktop'){ WVM.CONTAINER_HEIGHT = $('#media-container-' + videoId).height(); }else{ WVM.CONTAINER_HEIGHT = $('#media-container-' + videoId + " .hlsvideo-wrapper").height() + $('#media-container-' + videoId + " .now-playing-container").height(); } } //var top = $('#media-container-' + videoId).offset().top; var offset = WVM.VIDEO_TOP + (WVM.VIDEO_HEIGHT / 2); var offsetBack = WVM.VIDEO_TOP; var changed = false; //console.log("VIDEOTOP: " + WVM.VIDEO_TOP); //console.log("VIDEOHEIGHT: " + WVM.VIDEO_HEIGHT); //console.log("scrolltop " + $(window).scrollTop()); //only float if playing var isPlaying = WVM['player_state' + videoId]['IS_PLAYING'] || WVM['player_state' + videoId]['AD_IS_PLAYING']; if(isPlaying){ $('.vjs-loading-spinner').hide(); } var offsetFloatAd = 99999999; if(deviceName == 'desktop' && $('#float_anchor').length > 0){ offsetFloatAd = $('#float_anchor').offset().top - WVM.VIDEO_HEIGHT; //console.log("float anchor offset top " + offsetFloatAd); } if($(window).scrollTop() > offset && isPlaying && !WVM['player_state' + videoId]['CANCEL_FLOATING']){ $('#media-placeholder-' + videoId).height(WVM.CONTAINER_HEIGHT); $('#media-placeholder-' + videoId).css('display', 'block'); if(!WVM.IS_FLOATING){ changed = true; } WVM.IS_FLOATING = true; $('#media-container-' + videoId).addClass('floating-video'); var sWidth = window.innerWidth || document.documentElement.clientWidth; var sHeight = window.innerHeight || document.documentElement.clientHeight; if(sWidth > 900 && WADS.IS_STICKING){ $('#media-container-' + videoId).addClass('desktop-ad-is-sticky'); } else if(WADS.IS_STICKING){ if(!TOP_AD_VIEWED){ $('#media-container-' + videoId).addClass('mobile-ad-is-sticky'); }else{ $('#media-container-' + videoId).addClass('mobile-ad-is-sticky-noad'); } } else if(!WADS.IS_STICKING){ if(!TOP_AD_VIEWED){ $('#media-container-' + videoId).removeClass('desktop-ad-is-sticky'); }else{ $('#media-container-' + videoId).addClass('desktop-ad-is-sticky-noad'); } } //set right var sWidth = window.innerWidth || document.documentElement.clientWidth; var sHeight = window.innerHeight || document.documentElement.clientHeight; if(deviceName == 'desktop' || sWidth > 900){ var leftPos2 = $('aside').get(0).getBoundingClientRect().left; var leftPos = $('aside').offset().left ; $('#media-container-' + videoId).css('left', leftPos + "px"); var newWidth = Math.floor(sWidth / 3.5); $('#media-container-' + videoId).css('width', newWidth + "px"); } else{ $('#media-container-' + videoId).css('width', "100% !important"); $('#media-container-' + videoId + ' .now-playing-container').css('display', 'block'); $('#media-container-' + videoId + ' .next-dropdown-accordion').css('display', 'block'); } //floating-video $('#media-container-' + videoId + " " + '.page-carousel-wrapper').hide(); setTimeout(function(){ var hWrapper = $('.floating-video .hlsvideo-wrapper').height(); var npWidth = $('.floating-video .now-playing-container').height(); var ndWidth = $('.floating-video .next-dropdown-header').height() + 20; var scrollerHeight = sHeight - (hWrapper + npWidth + ndWidth); scrollerHeight = 180; //scrollerHeight = parseInt(scrollerHeight * 0.5); if(WVM.device_name == 'desktop'){ $('#media-container-' + videoId + " " + " .mobile-list-videos").height(scrollerHeight); } }, 100); }else if($(window).scrollTop() 0){ var container = document.querySelector('#page-carousel-' + fullVideoId); imagesLoaded( container, function() { var screenWidth = window.innerWidth || document.documentElement.clientWidth; if(screenWidth > 850){ WVM.IS_DESKTOP = true; $('#page-carousel-' + fullVideoId + ' .page-carousel-lg-slides').css('display', 'block'); WVM['player_settings' + fullVideoId].slider = $('#page-carousel-' + fullVideoId).bxSlider({ maxSlides: 4, minSlides: 4, slideWidth: 305, infiniteLoop: false, hideControlOnEnd: true, useCSS: true, pager: false, slideMargin: 15, moveSlides: 1, nextText: '', prevText: '' }); }else{ WVM.IS_DESKTOP = false; $('.page-carousel-wrapper').css('display', 'block'); } }); } }; WVM.setupToggleButton = function(fullVideoId, player){ if($('.nextplay-switch-' + fullVideoId).length > 0){ new DG.OnOffSwitchAuto({ cls:'.nextplay-switch-' + fullVideoId, height: 24, trackColorOn:'#F9F9F9', trackColorOff:'#222', textColorOn: '#222', textColorOff: '#222', textOn:'On', textOff:'Off', listener:function(name, checked){ var theVal = 1; if(!checked){ theVal = 0; } $.ajax({ url: '/ajax/update_autoplay_video/', data: { autoplay_on: theVal }, type: 'POST', dataType: 'json', success: function(data) { WVM['player_settings' + fullVideoId]['autoplay'] = checked; }, error : function(){ console.log("Error loading video"); } }); } }); } }; WVM.setupAccordionButton = function(fullVideoId){ var deviceName = 'desktop'; $('#next-dropdown-accordion-button-' + fullVideoId).on('click', function(){ if($(this).find('i').hasClass('fa-chevron-up')){ //hide $(this).find('i').removeClass('fa-chevron-up'); $(this).find('i').addClass('fa-chevron-down'); if(deviceName == "desktop" && !$('#media-container-' + fullVideoId).hasClass('floating-video')){ $('#media-container-' + fullVideoId + " " + '.page-carousel-wrapper').slideUp(); $('#media-container-' + fullVideoId + " " + '.mobile-list-wrapper').hide(); }else{ $('#media-container-' + fullVideoId + " " + '.mobile-list-wrapper').slideUp(); $('#media-container-' + fullVideoId + " " + '.page-carousel-wrapper').hide(); } var currVideoId = WVM['player_state' + fullVideoId]['VIDEO_ID']; var nextVideoId = WVM.getNextPlaylistIndex(currVideoId); //playerId, mediaId, fieldName var myTitle = WVM.getPlaylistData(fullVideoId, nextVideoId, 'noprefixtitle'); //alert("Getting title " + myTitle); $('#video-slider-nexttitle' + fullVideoId).css('display', 'inline'); $('#video-slider-nexttitle' + fullVideoId).html(myTitle); }else{ //expand $(this).find('i').addClass('fa-chevron-up'); $(this).find('i').removeClass('fa-chevron-down'); $('#media-container-' + fullVideoId + " " + '.mobile-list-wrapper').css('display', 'block'); if(deviceName == "desktop" && !$('#media-container-' + fullVideoId).hasClass('floating-video')){ $('#media-container-' + fullVideoId + " " + '.page-carousel-wrapper').css('display', 'block'); $('#media-container-' + fullVideoId + " " + '.page-carousel-wrapper').slideDown(); $('#media-container-' + fullVideoId + " " + '.mobile-list-wrapper').hide(); if(!WVM.player_state155200['CAROUSEL_INIT']){ WVM.setupCarousel(fullVideoId); } }else{ $('#media-container-' + fullVideoId + " " + '.mobile-list-wrapper').slideDown(); $('#media-container-' + fullVideoId + " " + '.page-carousel-wrapper').hide(); if(!$('#media-container-' + fullVideoId).hasClass('floating-video')){ if(!WVM.player_state155200['CAROUSEL_INIT']){ WVM.setupCarousel(fullVideoId); } } } $('#video-slider-nexttitle' + fullVideoId).css('display', 'none'); } }); var currVideoId = WVM['player_state' + fullVideoId]['VIDEO_ID']; //console.log("current Video " + currVideoId); var nextVideoId = WVM.getNextPlaylistIndex(currVideoId); var myTitle = WVM.getPlaylistData(fullVideoId, nextVideoId, 'noprefixtitle'); //console.log("setting title " + myTitle); $('#video-slider-nexttitle' + fullVideoId).css('display', 'inline'); $('#video-slider-nexttitle' + fullVideoId).html(myTitle); }; WVM.sendbeacon = function(action, nonInteraction, value, eventLabel) { var eventCategory = 'Video'; if (window.ga) { //console.log("sending action: " + action + " val: " + value + " label " + eventLabel); ga('send', 'event', { 'eventCategory': eventCategory, 'eventAction': action, 'eventLabel': eventLabel, 'eventValue': value, 'nonInteraction': nonInteraction }); } }; WVM.getNextPlaylistIndex = function(mediaId, returnArrayIndex){ var currId = null; if(mediaId == null){ return null; } for(var x =0; x 20){ if(fullDuration > 1 && ((fullDuration - fullCurrent) > 1) && !$('.vjs-loading-spinner').hasClass('badspinner')){ console.log("hiding spinner"); $('.vjs-loading-spinner').addClass('badspinner'); } } var duration_time = Math.floor(this.duration()); //this is a hack because the end video event is not firing... var current_time = Math.floor(this.currentTime()); if ( current_time > 0 && ( fullCurrent >= (fullDuration - 10) )){ var currId = playerState.VIDEO_ID; var newMediaId = WVM.getNextPlaylistIndex(currId); //if(playerSettings.autoplay_next && newMediaId){ if(newMediaId){ if('desktop' == "iphone" && playerState.AD_ERROR){ console.log("skipped timeupdate end"); }else{ WVM.load_video(newMediaId, true, playerState.ORIGINAL_ID); } } } if(!playerState.START_SENT){ WVM.sendbeacon('start', true, playerState.VIDEO_ID, playerState.VIDEO_TITLE); playerState.START_SENT = true; } var currentTime, duration, percent, percentPlayed, _i; currentTime = Math.round(this.currentTime()); duration = Math.round(this.duration()); percentPlayed = Math.round(currentTime / duration * 100); for (percent = _i = 0; _i = percent && __indexOf.call(playerState['PERCENTS_TRACKED'], percent) 0) { playerState['PERCENTS_TRACKED'].push(percent); } } } }); //player.off('ended'); player.on('ended', function(){ console.log("ended"); playerState.IS_PLAYING = false; WVM.sendbeacon("complete", true, playerState.VIDEO_ID, playerState.VIDEO_TITLE); var currId = playerState.VIDEO_ID; var newMediaId = WVM.getNextPlaylistIndex(currId); //if(playerSettings.autoplay_next && newMediaId){ if(newMediaId){ WVM.load_video(newMediaId, true, playerState.ORIGINAL_ID); }else{ console.log("Playlist complete (no more videos)"); } }); //player.off('adserror'); player.on('adserror', function(e){ //$('#ima-ad-container').remove(); WVM.lastAdRequest = new Date().getTime() / 1000; console.log(e); console.log("ads error"); var errMessage = e['data']['AdError']['l']; playerState.AD_IS_PLAYING = false; playerState.IS_PLAYING = false; // && errMessage == 'The VAST response document is empty.' if(!playerState.AD_ERROR){ var dTime = new Date().getTime(); WVM.firstPrerollTagUrl = WVM.getFirstPrerollUrl(); console.log("calling backup ad tag url: " + WVM.firstPrerollTagUrl); WVM.activePlayer.ima.changeAdTag(WVM.firstPrerollTagUrl + "?" + dTime); WVM.activePlayer.ima.requestAds(); //WVM.activePlayer.src({ // src: masterSrc, // type: 'video/mp4' //}); //WVM.firstPrerollTagUrl = ""; } playerState.AD_ERROR = true; }); //player.off('error'); player.on('error', function(event) { if (player.error().code === 4) { player.error(null); // clear out the old error player.options().sources.shift(); // drop the highest precedence source console.log("now doing src"); console.log(player.options().sources[0]); player.src(player.options().sources[0]); // retry return; } }); //player.off('volumechange'); player.on('volumechange', function(event) { console.log(event); var theHeight = $('#media-container-' + playerState.ORIGINAL_ID + ' .vjs-volume-level').css('height'); var cssVolume = 0; if(theHeight){ cssVolume = parseInt(theHeight.replace('%', '')); } var theVolume = player.volume(); if(theVolume > 0.0 || cssVolume > 0){ $('#media-container-' + playerState.ORIGINAL_ID + ' .mute-overlay').css('display', 'none'); }else{ $('#media-container-' + playerState.ORIGINAL_ID + ' .mute-overlay').css('display', 'block'); } }); WVM.reinitRawEvents(playerState.ORIGINAL_ID); setInterval(function(){ WVM.reinitRawEvents(playerState.ORIGINAL_ID); }, 2000); } if(!WVM.rawCompleteEvent){ WVM.rawCompleteEvent = function(e){ var playerState = WVM['player_state155200']; console.log("firing raw event due to all other events failing"); var currId = playerState.VIDEO_ID; var newMediaId = WVM.getNextPlaylistIndex(currId); //if(playerSettings.autoplay_next && newMediaId){ if(newMediaId){ WVM.load_video(newMediaId, true, playerState.ORIGINAL_ID); } }; } if(!WVM.rawTimeupdateEvent){ WVM.rawTimeupdateEvent = function(e){ var playerState = WVM['player_state155200']; var rawVideoElem = document.getElementById('html5-video-' + playerState['ORIGINAL_ID'] + '_html5_api'); var fullCurrent = rawVideoElem.currentTime * 1000; var fullDuration = rawVideoElem.duration * 1000; var current_time = Math.floor(rawVideoElem.currentTime); console.log("raw timeupdate: " + fullCurrent + " out of " + fullDuration); if ( current_time > 0 && ( fullCurrent >= (fullDuration - 50) )){ var currId = playerState.VIDEO_ID; var newMediaId = WVM.getNextPlaylistIndex(currId); if(newMediaId){ console.log("loading new video from rawtimeupdate"); WVM.load_video(newMediaId, true, playerState.ORIGINAL_ID); } } if(!$('.vjs-loading-spinner').hasClass('badspinner')){ $('.vjs-loading-spinner').addClass('badspinner') } }; } WVM.reinitRawEvents = function(playerId){ var playerState = WVM['player_state' + playerId]; var rawVideoElem = document.getElementById('html5-video-' + WVM['player_state' + playerId]['ORIGINAL_ID'] + '_html5_api'); //COMPLETE EENT if( WVM['player_state' + playerId].COMPLETE_EVENT){ rawVideoElem.removeEventListener('ended', WVM.rawCompleteEvent, false); } rawVideoElem.addEventListener('ended', WVM.rawCompleteEvent, false); //TIME UPDATE EVENT if( WVM['player_state' + playerId].TIMEUPDATE_EVENT){ rawVideoElem.removeEventListener('ended', WVM.rawTimeupdateEvent, false); } rawVideoElem.addEventListener('ended', WVM.rawTimeupdateEvent, false); WVM['player_state' + playerId].COMPLETE_EVENT = true; WVM['player_state' + playerId].TIMEUPDATE_EVENT = true; };

MILWAUKEE (CBS 58) -- A federally published study shows a high level of physical activity is linked with improved vaccine responses in older adults, so could what we eat and how we exercise help improve how our immunity responds to the COVID-19 vaccine?

Experts say its no secret that exercise improves immune function, and they say you dont have to do too much to reap the benefits.

The concept essentially is to simply get your heart rate up higher than if you were sitting down, so that can simply be a brisk walk, says Nicole Kerneen, a registered and certified dietitian and personal trainer at Way of Life Nutrition and Fitness.

Registered dietitians say your immune system will see a boost with consistent light exercise. If you dont exercise regularly but do decide to prior to getting a vaccine, Kerneen says there are still some benefits.

Youll have a lot more circulation happening, you also have all of the immune receptors really alert, and so that in turn can essentially help, she adds.

Experts say some sort of upper body movement after getting a vaccine isnt a bad idea either.

Post-vaccination, if youre able to and feeling well enough of course, without stressing the body too much, engage in some light activity. That can actually promote circulation which can support our immune systems response said Cassie Vanderwall, a clinical nutritionist at UW Health.

As simple as with no weight at all and youre just moving your arm up and down, youre stretching it and allowing it to move, Kerneen adds.

Vanderwall says certain foods can also cause inflammation, which affects immune response.

High sugary processed foods, those are pro-inflammatory, meaning theyre going to light the fire, were actually looking for foods that are going to put out or calm down the fire, she says.

Kerneen says when it comes to improving immunity with food, consistency is key, but eating something unhealthy every once in a while is still okay. Dieticians suggest foods like leafy green vegetables, berries, citrus, garlic and onions.

Those things are incredible for your body and for your immune system and to decrease inflammation, says Kerneen.

Salmon or walnuts, nuts and seeds. A meal composed of those items post-vaccine, pre-vaccine or every day is really going to help, Vanderwall said.

On top of diet and exercise, experts say good rest and hydration can also provide good circulation before and after you get a COVID-19 vaccine.

See the rest here:
Experts say healthy diet and light exercise may boost immune response to the COVID-19 vaccine - WDJT

Read More...

Insights into how COVID outsmarts the gut’s immune response could point to new treatments – FierceBiotech

May 2nd, 2021 1:53 am

Scientists studying SARS-CoV-2, the virus behind COVID-19, have known since the early days of the pandemic that it can infect the stomach. But how the gut mounts an immune response to the virus is still largely a mystery.

A team from the European Molecular Biology Laboratory (EMBL) used live models of the human gut to study how intestinal cells respond to COVID-19and what they learned could inform efforts to develop new therapies, they said.

The researchers discovered that SARS-CoV-2 disrupts interferon signaling in certain gut cells to cause an inflammatory immune response to the virus. They described their findings in the journal Molecular Systems Biology.

RELATED: Gut bacteria point to novel strategies for combating asthma, COVID-19

The EMBL team started by creating 3D tissue models, or organoids, of the human gut. The models allowed them to determine that a particular subpopulation of cells called enterocytes are most affected by SARS-CoV-2.

They used single-cell RNA sequencing to track cell activity as the disease progressed, observing how the enterocytes triggered a response from the immune system by scrutinizing the activity of 12 genes.

The researchers were surprised to discover that the enterocytes most affected by the virus did not display high levels of ACE2, a cell-surface receptor that has previously been fingered as a culprit in causing COVID-19 infection. Furthermore, they found that infected gut cells mounted a pro-inflammatory response to the virus by pumping up levels of the transcription factor NFkB and the cytokine TNF.

Interferon-stimulated genes were only dialed up in bystander cells, suggesting COVID-infected cells were actively blocking interferon signaling, the EMBL researchers concluded.

The guts role in respiratory diseases has piqued the interest of other research teams, including one at Monash University in Australia. Researchers there suggested earlier this year that L-tyrosine metabolized by gut microbes might shield the lungs from inflammation. They demonstrated that over-the-counter L-tyrosine supplements were effective in mouse models of acute respiratory distress syndrome, which can occur in severe cases of COVID-19.

The variety of immune responses that the EMBL researchers found among different cells of the gut suggest that there are cell type-specific or tissue-specific regulations of interferon-mediated signaling during SARS-CoV-2 infection, they wrote in the study. This needs to be considered when studying replication and pathogenesis of SARS-CoV-2 in different organs as well as when developing therapies against COVID-19.

View post:
Insights into how COVID outsmarts the gut's immune response could point to new treatments - FierceBiotech

Read More...

How can you improve your immune system in the second wave of COVID? – The Bridge

May 2nd, 2021 1:53 am

A high immunity is always credited for various reasons such as a good diet, exercise, minimal health complications, etc. The benefits of having a functional and stable immune system are phenomenal with the most prominent one being the prevention of diseases and infections. The harmful short and long-term effects of Covid 19 cannot be stressed enough and by now it is evident that there need to be proactive countermeasures to deal with the same. Here are some tips and tricks to ramp up the functioning of an immune system of a person with basic self-care measures

A balanced diet is one of the best possible ways of fighting infections. Food items such as vegetables, fruits, pulses, meat, milk products all have the necessary nutritional requirements for the body to counter certain viral infections that may be sourced externally. It is not necessary to have high protein or high fat (or any particular nutrient) but it should be a combination of everything that the body is receptive towards in a normal course of life.

While many might consider this to be a mental aspect of immunity, the phrase 'healthy mind, healthy body' is true. Stress levels have been found to directly contribute to aggravating an infection or disease in a body simply due to lack of adequate care or ignorance of symptoms. It might be easier said than done but activities like meditation, cooking, exercising, carrying out hobbies, etc are all big stress relievers.

The impact of Covid 19 during the second wave has been disastrous, to say the least. Breathing exercises, drinking warm water frequently, taking care of a person's physical and mental health are just a few more ways of ensuring that there is adequate immunity. Immunity booster medication too might help as an external means but for one to truly help the body be physically and mentally ready, it is necessary to be consistent with the physical and mental requirements on a day-to-day basis.

View post:
How can you improve your immune system in the second wave of COVID? - The Bridge

Read More...

Pfizer vs. Moderna Vaccines: Does One Have More Side Effects Than the Other? – NBC Chicago

May 2nd, 2021 1:53 am

As many continue receiving their first or second doses of the Pfizer and Moderna COVID vaccines currently available, what are the potential side effects and does one cause more side effects than the other?

Chicago Department of Public Health Commissioner Dr. Allison Arwady was recently asked that very question.

There have also been reports of potential symptoms like "COVID arm" or changes in menstrual cycles.

Here's what we know so far about the two mRNA vaccines and their side effects:

Side effects are possible after receiving any COVID vaccine currently being administered in the U.S.

Experiencing side effects isn't necessarily a bad thing. In fact, it's a sign your body is responding.

"That's just your immune system learning the lesson of how to fight it off," Chicago's top doctor said in a Facebook Live Tuesday. "So people who have stronger side effects, it's just a sign that you have a very robust strong immune system that's learning the lesson."

The CDC reports the most common side effects for the vaccines is at the injection site. They include:

Common side effects in the body include:

The Centers for Disease Control and Prevention advises people to stick around for 15 minutes after vaccination, and those with a history of other allergies for 30 minutes, so they can be monitored and treated immediately if they have a reaction.

Recent reports have brought to light some other unexpected but so far not serious side effects that could be related to the vaccines, experts say.

As more and more Americans receive their first or second doses of the Pfizer or Moderna COVID vaccines every single day, some people who menstruate are reporting changes to their periods after getting vaccinated.

Dr. Kate Clancy, an associate professor of anthropology at the University of Illinois, posted her experience on Twitter in February and received hundreds of reports from those experiencing what she pondered could be a little-publicized response to the two available mRNAvaccines.

Chicago Department of Public Health Commissioner Dr. Allison Arwady was asked about the possibility of vaccinations impacting menstruation in a Facebook live broadcast last week.

"Two hundred and twenty million Americans have gotten a first dose of vaccine, right? So, among 220 million Americans, there are people who will have, you know a herpes outbreak, who will have a changed menstruation cycle, etc.," she said. "What has been interesting, I think, is that, that this has really raised some awareness for wanting to make sure that we're asking questions about things like changes in menstruation, right? Most vaccine trials, most trials in general actually, unless they're really focused on women's reproductive health, may not even ask questions like that and that perhaps points to some biases in terms of how, you know, trials in general for medications, etc. are set up."

"I have not seen anything, to be very clear, that suggests that there is any concerning side effects in the way that would last, I know and there's a local researcher who is looking at some of this related menstruation, but very clear there's not been any link to, you know, problems with fertility, you know, anything that's long-lasting but, you know, the goal of getting a vaccine is for your immune system to learn how to protect yourself against COVID and your immune system can interact, can interface with your, you know, your hormonal levels, etc. and so there is at least some biological plausibility that you could have, you know, some change in terms of a heavier period or a lighter period for example right after getting the vaccination," Arwady continued.

Health experts have noted that menstrual changes have been documented in recent months outside of vaccinations as well.

Dr. Whitney Lyn, a Family Medicine attendee for Cook County Health, acknowledged the possibility of changes post-vaccination, but also noted that stress can also play a role in a woman's cycle.

"Women's menstrual cycle can, you know, always change month to month for various reasons," Lyn said. "And so one of the things that causes a woman's menstrual just to change is stress and so right now we're seeing a very stressful time. And so every time someone gets the vaccine, they're a little stressed out, so sometimes can that make your flow a little heavier or a little lighter? Yes. And so, I think it's a normal response, but I don't think it's a reason not to take the vaccine."

Even without contracting COVID or getting vaccinated, menstrual changes have been reported possibly stemming from the overall pandemic environment itself. AWashington Post report from Augustfound that several gynecologists "confirmed that many of their patients are reporting skipped periods or have noticed increases or decreases in cycle length, blood volume and level of menstrual-related pain."

There have also been reports of what's known as "COVID arm," a term used to describe delayed skin reactions such as rashes, which appear days after injection.

"If it is going to arise, it usually appears about a week after your vaccine,Dr. Brita Roy, an internal medicine physician and director of population health for Yale Medicine said. Its a red, swollen area at the site of the shot."

The skin reactions gained attention when a letter was published in theNew England Journal of Medicineearlier this month detailing some patients who experienced varying degrees of arm rashes following their first dose of the Moderna vaccine.

Its not super common, but its not uncommon. Its a delayed hypersensitivity, similar to what you may see if you get poison ivy, Roy said. You maybe came into contact with the poison ivy in your yard, but some people wont get a rash until a few days later.

The Centers for Disease Control and Prevention has acknowledged reports "that some people have experienced a red, itchy, swollen, or painful rash where they got the shot," which it identified as "COVID arm."

According to theCDC, the rashes can start within a few days to more than a week after the first shot and "are sometimes quite large."

"If you experience 'COVID arm' after getting the first shot,you should still get the second shotat the recommended interval if the vaccine you got needs a second shot," the CDC noted. "Tell your vaccination provider that you experienced a rash or 'COVID arm' after the first shot. Your vaccination provider may recommend that you get the second shot in the opposite arm."

The CDC said those who experience COVID arm can take an antihistamine.

"If it is painful, you can take a pain medication like acetaminophen or a non-steroidal anti-inflammatory drug (NSAID)," the CDC recommends.

According to Pfizer, about 3.8% of their clinical trial participants experienced fatigue as a side effect and 2% got a headache.

Moderna says 9.7% of their participants felt fatigued and 4.5% got a headache.

But experts say data shows the two are similar and that side effects depend more on the person than shot itself.

"I would not try to make a decision between one, you know, between Moderna and Pfizer in particular, based on side effects," Arwady said Tuesday. "I think get the one that's available to you and do definitely get that second dose."

With the two-shot vaccines, people are more likely to report side effects after their second dose, experts have said.

According to the CDC, side effects after your second shot "may be more intense than the ones you experienced after your first shot."

"These side effects are normal signs that your body is building protection and should go away within a few days," the CDC states.

In trials of both the Moderna and Pfizer vaccines, more people experienced side effects after the second dose.

Arwady noted that a good indicator of whether you'll experience side effects after your second dose is how your body reacted to the first.

"The biggest predictor between first and second doses is what your own reaction was," she said. "So if you didn't have much of a reaction after the first dose, you're unlikely to have a big reaction after the second dose. We do see people having a little more side effects after the second dose than the first but usually not a huge, huge amount of difference."

She added that Johnson & Johnson's vaccine "does have a lower rate of the side effects in those first few days than the other two do."

But that doesn't mean that you shouldn't get your second shot if you get side effects after your first, experts say.

When people receive that second dose, they are receiving the second booster to try and reach the maximum efficacy," said Dr. Edward Cachay, infectious disease specialist at UCSD.

The CDC also noted that both shots are needed.

"ThePfizer-BioNTech COVID-19 VaccineandModerna COVID-19 Vaccineboth need 2 shotsin order to get the most protection," the CDC states. "You should get the second shot even if you have side effects after the first shot, unless a vaccination provider or your doctor tells younot to get it."

There are also some factors that could make you more likely to experience side effects.

Chicago's top doctor said Tuesday that the biggest predictor for side effects so far has been age.

"Older people, broadly, do not have as much side effects and that's because their immune systems are not quite as robust, generally and so they don't mount as much of a immune response," Arwady said. "It doesn't mean that they're not protected."

According to Loafman, the body's immune system is what creates the symptoms.

"That's simply a reflection of the immune response, just the way we have when we get ill," he said.

Arwady also noted that women are more likely to report side effects than men.

"Some of this is because women may just be better reporters... but there probably is something real to this too because something else interesting for those who may not know as much about immunity is that autoimmune diseases? Much, more likely in women, too," Arwady said. "And even the, like, more serious like the allergic reactions, the more serious allergic reactions? More likely in women."

Why is that?

Arwady said estrogen can elevate immune responses, while testosterone can decrease it. At the same time, she noted that "a lot of your immune modulating genes" can live on an "x" chromosome, which women have two of, while men have one.

"So there's all these reasons that sort of immunity in general goes up a little bit different in women than it does in men," she said. "And so we're seeing women, a little more likely to report some of the side effects."

Data from the CDC also reported women were more likely to experience side effects than men, according monitoring from the first month of vaccinations.

From Dec. 14 through Jan. 13, more than 79 percent of side effects were reported by women, the data showed. Meanwhile, women received roughly 61.2 percent of the doses administered during that same time.

Side effects could also vary depending on whether or not you've had coronavirus.

"We have seen more likely that people will report some side effects because that is acting a little bit like a booster dose to your immune system," Arwady said. "Your immune system has already learned some of those lessons of how to protect itself, not in as long a way not as protective a way."

"That is also probably that booster effect," Arwady said.

Loafman agrees.

"If you had COVID a while ago or you've already got some immunity, it's more like a booster," he said. "And boosters for some people are completely asymptomatic, boosters for other people trigger their immune response against it so they have some inflammation with it."

But not getting side effects isn't a negative, health experts say.

"If you don't get side effects it does not mean that you are not protected," Arwady said. "I want to be really clear about that."

According to Loafman, it simply means "your body didn't react with as much of an inflammatory response.

"You're still making antibodies," he said.

According to Loafman, every person's response is unique.

"It's really just kind of a reflection of how unique each of our systems are, what other immunities we have," he said. "You know, a lot of the antibodies cross react and we have cross reactivity so it's really a mosaic. Each of our immune systems is a mosaic composite of all that we've been through and all that we have and all we've recently been dealing with. Our individual response varies. Everybody gets gets the appropriate immune response."

Questions about vaccine effectiveness have been paired with a rise in spread of multiple COVID variants.

So far, studies suggest that the vaccines currently in use can recognize the emerging variants but theymay not provide as much protectionagainst the new strains.

Pfizer's latest study results, however, suggested that the vaccine is effective against the coronavirus variant that first emerged in South Africa.

These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population," Ugur Sahin, CEO and co-founder of BioNTech, said in a statement.

Moderna, citing data from its phase three clinic trial, reported its COVID-19 vaccine was more than 90% effective at protecting against COVID and more than 95% effective against severe disease up to six months after the second dose, the company said.

But boosters and new versions of vaccines that target the variants are already being explored.

Pfizer-BioNTech is testing a third booster shotof its vaccine on fully vaccinated people. PfizerCEO Albert Bourla said people will "likely" need a third dose of a COVID-19 vaccine within 12 months of getting fully vaccinated.

"The flexibility of our proprietary mRNA vaccine platform allows us to technically develop booster vaccines within weeks, if needed," Ugur Sahin, CEO and co-founder of BioNTech, said in arelease.

Late last month, the National Institutes of Health started testing a new COVID vaccine from Moderna aimed at protecting against a variant first discovered in South Africa. Moderna CEO Stephane Bancel told CNBC that the companyhopes to have a booster shotfor its two-dose vaccine available in the fall.

But what about without the variants?

In clinical trials,Moderna's vaccine reported 94.1% effectivenessat preventing COVID-19 in people who received both doses. ThePfizer-BioNTech vaccinewas said to be 95% effective.

A new CDC study reported that a single dose of Pfizer's or Moderna's COVID vaccine was 80% effective in preventing infections. That number jumped to 90% two weeks after the second dose, the study on vaccinated health care workers showed.

"These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions," the U.S. agency wrote in the study. "COVID-19 vaccination is recommended for all eligible persons."

It is not known if any of the vaccines prevent the spread of the virus by people who are asymptomatic.

Monica Hendrickson, public health administrator for the Peoria County Health Department noted that the vaccines each hold a high effectiveness against death and severe illness for coronavirus.

"So, really, you're looking at a distinction that from a clinical standpoint, or from, you know, an epidemiological standpoint is very minor compared to what we really are hoping for, which is decreases in death and decreases in severe illness, where they all match up between the three vaccines," Hendrickson said. "Most important thing though is that when these vaccines come on the market, if you have an option to any of these, get one of them."

Hendrickson's message echoes one made by Dr. Marina Del Rios, emergency medicine specialist at the University of Illinois-Chicago,during NBC 5's "Vaccinated State" panel.

Part of my messaging in the community has been that the vaccines on the market are equally efficacious and equally safe," Del Rios said. "The best vaccine you can get is the one that you can get ahold of first, and getting vaccinated earlier, sooner rather than later, protects us from getting sick ourselves and also our community, which has been so terribly devastated by this virus.

Continued here:
Pfizer vs. Moderna Vaccines: Does One Have More Side Effects Than the Other? - NBC Chicago

Read More...

Family Healthcast: can alcohol consumption reduce your immunity to COVID? – WSYR

May 2nd, 2021 1:53 am

Posted: Apr 30, 2021 / 06:14 PM EDT / Updated: Apr 30, 2021 / 06:15 PM EDT

FAMILY HEALTHCAST After a long year and a lot of anticipation, getting the COVID-19 vaccine can be cause for celebration, which for some might mean pouring a drink and toasting to their new immunity. But can alcohol interfere with your immune response?

The short answer is that it depends on how much you drink. Heavy alcohol consumption, particularly over the long term, can suppress the immune system and potentially interfere with your vaccine response according to experts.

Since it can take weeks after a COVID shot for the body to generate protective levels of antibodies against the virus, anything that interferes with the immune response would be cause for concern.

There is no evidence that moderate drinking around or after being vaccinated makes the shots less effective. Some studies have even found that over the longer term, small or moderate amounts of alcohol might actually benefit the immune system by reducing inflammation.

Moderate drinking is generally defined as no more than two drinks a day for men and a maximum of one drink a day for women, whereas heavy drinking is defined as four or more drinks for men and three for women.

Another reason to moderate your alcohol intake is that heavy drinking, along with the hangover that might ensue, can potentially amplify any side effects you might have from the COVID vaccine, including fever, fatigue or body aches.

However, doctors say having a glass of champagne probably wont inhibit any immune response, celebratory alcoholic beverages in moderation are fine.

See the article here:
Family Healthcast: can alcohol consumption reduce your immunity to COVID? - WSYR

Read More...

‘Smart’ immune cells kill tumours and stop them regrowing in mice – New Scientist News

May 2nd, 2021 1:53 am

By Michael Le Page

A person having blood drawn for CAR-T therapy

GERARD JULIEN/AFP via Getty Images

Immune cells programmed to attack tumours in a smarter way have shrunk brain and ovarian tumours in mice studies where unaltered immune cells failed. The technology could be used to treat cancers as well as degenerative brain disorders.

We have more control over what the cell does when it reaches the disease site, says Kole Roybal at the University of California, San Francisco. We can really program in very specific functions.

Advertisement

Our bodies naturally kill off many nascent cancers, but sometimes immune cells called T-cells dont recognise cancerous cells. One way to treat cancers that manage to dodge the immune system is to genetically engineer T-cells to produce a receptor that helps them target a specific protein on thecancer cells surface. These are called CAR T-cells, where CAR stands for chimeric antigen receptor.

CAR-T therapies have cured a few people, leading the US to approve two forms in 2017. But there are major limitations. The approach has only been effective against blood cancers such as leukaemia, not against solid tumours. And it can have very serious even fatal side effects if the T-cells kill off non-cancerous cells that also have the target protein on their surface.

These problems are related. One of the reasons why CAR-T therapies dont work for solid tumours is that not all cells in such tumours express a single, unique protein, says Roybal. So his team has developed a new type of receptor protein that works in a different way. Instead of triggering an instant attack, these T-cell receptors switch on any desired gene or genes when they recognise a target protein. This can be any protein the researchers choose, which is why the technique can be used for brain disorders in addition to cancers.

Roybals team engineered this receptor to recognise a protein specific to some cells in brain tumours called glioblastomas. The receptor then activated a gene for a standard CAR-T receptor that targets a protein found on a wider range of tumour cells and on healthy cells. Crucially, though, the killing effect was limited to tumour environments where both proteins are present: if the engineered cells leave the tumour, the CAR-T gene gets switched off again.

In tests in mice, this approach shrunk glioblastomas and prevented recurrence where conventional CAR-T therapies either didnt work or didnt prevent regrowth. In a separate animal study, similar results were found for ovarian cancers and mesotheliomas, which are mostly caused by asbestos.

Standard CAR T-cells seem to become exhausted relatively quickly and die off, says Roybal. The smart CAR T-cells persisted for longer in the body, which is important for preventing recurrence, he says.

We are solving a load of the roadblocks in solid tumours, says Roybal. We are not all the way there, theres a lot of work to do, but we have taken major steps.

For instance, tumours often release factors that suppress an immune response. His team plans to engineer the smart CAR-T cells to release other factors that counteract this, and stimulate a broader immune response against tumours.

His team is also getting the therapies used in the mice ready for human trials, which could take a couple of years. These trials will involve removing a patients immune cells and genetically engineering them before putting them back in the body. In the longer term, it may be possible to treat people using off-the-shelf cells, which would greatly reduce costs.

Journal References: Science Translational Medicine, DOI: 10.1126/scitranslmed.abe7378 & 10.1126/scitranslmed.abd8836

Sign up to our free Health Check newsletter for a round-up of all the health and fitness news you need to know, every Saturday

We clarified which type of tumours were shrunk by the immune cells

More on these topics:

More:
'Smart' immune cells kill tumours and stop them regrowing in mice - New Scientist News

Read More...

Seven supplements to support your immune system – The Tri-City News

May 2nd, 2021 1:53 am

When it comes to keeping your immune system strong to fight off colds and flu, certain supplements can give your body the boost it needs

Staying healthy is at the top of everyones minds these days.

Fortunately, Popeyes Supplements in Coquitlam and Burnaby offer a welcoming environment for anyone interested in supporting their health.

We pride ourselves on outstanding customer service, owner Brad Alderson says.

We have the best selection of all the top brand name supplements and vitamins in Canada at the lowest prices. We strive to help our customers exceed their health and fitness goals.

When it comes to keeping your immune system strong to fight off colds and flu, certain supplements can give your body the boost it needs.

Alderson recommends the following seven supplements to support your immune system, all available in-store at Popeyes, and on thewebsite.

VegeGreens is a comprehensive combination of over 60 land, sea, and cruciferous vegetables as well as super green food, herbal extracts and botanicals. Each small scoop provides the nutrient equivalent of six to eight servings of fresh vegetables.

This supplement helps increase energy and renew mental clarity, cleanse your body, strengthen immune function, and balance your pH. It also supports your heart, liver and digestive health.

PhytoBerry is a highly concentrated berry-based whole food supplement thats loaded with natural antioxidants. Featuring over 40 fruit concentrates, PhytoBerry is specifically designed to offer whole body antioxidant protection. A single serving has the equivalent nutrient content of six to eight servings of fresh fruit.

This supplement supports immune functions, provides antioxidant protection for your entire body, and increases energy.

Dont overlook the power of vitamins when it comes to boosting your immune system. Progressive Vitamin D3 can help with the maintenance of good health.

Vitamin D3 provides immune system support, promotes the development of healthy bones and teeth, and helps the body absorb calcium.

Progressive Vitamin C Complex provides isolated sources of vitamin C for increased potency. The plant-based digestive support of papaya and black pepper extract increase the absorption and maximize the health-promoting properties of the entire formula.

The Vitamin C Complex provides powerful antioxidant protection, supports cardiovascular health and immune function, and promotes healthy bones, joints, teeth, and gums.

Precision All Natural Whey Isolate features a gently processed, low-temperature filtered whey protein isolate imported from New Zealand. New Zealand proteins are considered to be the cleanest in the world. The cattle there are raised without the use of growth-regulating steroids or milk-inducing hormones (including rBGH). Also, the milk supply is routinely screened for over 200 agricultural and chemical contaminants.

This form of New Zealand isolate is an excellent source of dietary protein and will help build muscle and repair lean body tissue. It is anabolic and gluten free, low in fat and cholesterol, and provides a broad range of amino acids.

Precision All Natural Whey Isolate tastes great and easily blends into a rich and creamy high protein shake or smoothie. Its the perfect choice for people with active lifestyles or for anyone wishing to increase their protein intake while avoiding artificial ingredients.

Medicinal mushrooms have a history of use in traditional medicine stretching back thousands of years. Each mushroom offers its own nutritional profile and therapeutic potential.

Mushrooms help increase energy and support resistance to stress. Mushrooms are also used to support the immune system.

Probiotics are helpful bacteria that keep your gut healthy. They support intestinal health and help with digestive challenges.

Alderson recommends two products Popeyes offers:

Perfect Probiotic Colon Support, part of the worlds first TRU-ID Certified probiotic family which guarantees every species listed on the label is included in every capsule.

The other option is Perfect Probiotic 60 Billion, an extra-strength probiotic for daily use and supports intestinal health when you feel off.

To learn more and to order the best deals on nutritional supplements online, visit http://www.popeyesbc.ca.

Read more from the original source:
Seven supplements to support your immune system - The Tri-City News

Read More...

You Don’t Have to Suffer to Benefit From COVID Vaccination But Some Prefer It – HealthLeaders Media

May 2nd, 2021 1:53 am

This article was published on Wednesday, April 28, 2021 in Kaiser Health News.

By Arthur Allen

If you think vaccination is an ordeal now, consider the 18th-century version. After having pus from a smallpox boil scratched into your arm, you would be subject to three weeks of fever, sweats, chills, bleeding and purging with dangerous medicines, accompanied by hymns, prayers and hell-fire sermons by dour preachers.

That was smallpox vaccination, back then. The process generally worked and was preferred to enduring "natural" smallpox, which killed around a third of those who got it. Patients were often grateful for trial-by-immunization once it was over, anyway.

"Thus through the Mercy of God, I have been preserved through the Distemper of the Small Pox," wrote one Peter Thatcher in 1764, after undergoing the process in a Boston inoculation hospital. "Many and heinous have been my sins, but I hope they will be washed away."

Today, Americans are once again surprisingly willing, even eager, to suffer a little for the reward of immunity from a virus that has turned the world upside down.

Roughly half of those vaccinated with the Moderna or Pfizer-BioNTech vaccines, and in particular women, experience unpleasantness, from hot, sore arms to chills, headache, fever and exhaustion. Sometimes they boast about the symptoms. They often welcome them.

Suspicion about what was in the shots grew in the mind of Patricia Mandatori, an Argentine immigrant in Los Angeles, when she hardly felt the needle going in after her first dose of the Moderna vaccine at a March appointment.

A day later, though, with satisfaction, she "felt like a truck hit me," Mandatori said. "When I started to feel rotten I said, 'Yay, I got the vaccination.' I was happy. I felt relieved."

While the symptoms show your immune system is responding to the vaccine in a way that will protect against disease, evidence from clinical trials showed that people with few or no symptoms were also protected. Don't feel bad if you don't feel bad, the experts say.

"This is the first vaccine in history where anyone has ever complained about not having symptoms," said immunologist Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia.

To be sure, there is some evidence of stronger immune response in younger people and in those who get sick when vaccinated. A small study at the University of Pennsylvania showed that people who reported systemic side effects such as fever, chills and headache may have had somewhat higher levels of antibodies. The large trial for Pfizer's vaccine showed the same trend in younger patients.

But that doesn't mean people who don't react to the vaccine severely are less protected, said Dr. Joanna Schaenman, an expert on infectious diseases and the immunology of aging at the David Geffen School of Medicine at UCLA. While the symptoms of illness are undoubtedly part of the immune response, the immune response that counts is protection, she said. "That is preserved across age groups and likely to be independent of whether you had local or systemic side effects or not."

The immune system responses that produce post-vaccination symptoms are thought to be triggered by proteins called toll-like receptors, which reside on certain immune cells. These receptors are less functional in older people, who are also likely to have chronic, low-grade activation of their immune systems that paradoxically mutes the more rapid response to a vaccine.

But other parts of their immune systems are responding more gradually to the vaccine by creating the specific types of cells needed to protect against the coronavirus. These are the so-called memory B cells, which make antibodies to attack the virus, and "killer T cells" that track and destroy virus-infected cells.

Many other vaccines, including those that prevent hepatitis B and bacterial pneumonia, are highly effective while having relatively mild side effect profiles, Schaenman noted.

Whether you have a strong reaction to the vaccine "is an interesting but, in a sense, not vital question," said Dr. William Schaffner, a professor of infectious disease at Vanderbilt University Medical Center. The bottom line, he said: "Don't worry about it."

There was a time when doctors prescribed cod-liver oil and people thought medicine had to taste bad to be effective. People who get sick after COVID vaccination "feel like we've had a tiny bit of suffering, we've girded our loins against the real thing," said Schaenman (who had a slight fever). "When people don't have the side effects, they feel they've been robbed" of the experience.

Still, side effects can be a hopeful sign, especially when they end, says McCarty Memorial Christian Church leader Eddie Anderson, who has led efforts to vaccinate Black churchgoers in Los Angeles. He helps them through the rocky period by reminding them of the joyful reunions with children and grandchildren that will be possible post-vaccination.

"I'm a Christian pastor,'' he said. "I tell them, 'If you make it through the pain and discomfort, healing is on the other side. You can be fully human again.'"

This story was produced byKHN, which publishesCalifornia Healthline, an editorially independent service of theCalifornia Health Care Foundation.

Arthur Allen: ArthurA@kff.org, @ArthurAllen202

Kaiser Health News is a national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.

See the article here:
You Don't Have to Suffer to Benefit From COVID Vaccination But Some Prefer It - HealthLeaders Media

Read More...

Vaccines do provide immunity and can be used to achieve herd immunity – Health Feedback

May 2nd, 2021 1:53 am

CLAIM

Vaccines dont promise immunity and therefore vaccine herd immunity doesnt exist.

DETAILS

Inaccurate: Contrary to the claim, vaccines, which train a persons immune system to respond to pathogens, provide immunity and are the safest strategy for achieving herd immunity. Natural infection also provides immunity, but achieving herd immunity through infection would result in unnecessary cases of the disease and deaths.

KEY TAKE AWAY

Herd immunity occurs when a significant portion of a population is immune to a pathogen, making it difficult for the pathogen to spread through the population. Apart from protecting vaccinated individuals, herd immunity provides indirect protection from infection even to individuals who are unable to be vaccinated. One strategy to achieve herd immunity is through vaccination, which provides protective immunity to vaccinated individuals.

REVIEW As COVID-19 vaccination campaigns move forward in a number of countries, journalists, healthcare professionals and scientists have raised the questions of when a country can expect to reach herd immunity and if they are close to reaching it.

Herd immunity is a concept that describes the point at which the population as a whole is protected from an infectious disease. This point occurs when enough people in a population or herd are protected from that disease, either through vaccination or through previous infection. This in turn protects even individuals susceptible to the disease, because they are a member of a herd where the majority are protected, making it unlikely for the susceptible individual to become infected.

To better understand the concept of herd immunity, picture 100 people in a room. When a new infectious disease appears, everyone is susceptible to the disease and each person, once infected, has the potential to spread that disease to their neighbors. However, if a large percentage of the population is immune, even if the disease infects one of the few susceptible individuals, the pathogen will have a hard time spreading because the majority is protected. When this is achieved, the population is considered to have herd immunity.

In an Instagram post published on 24 April 2021, Laura Elizabeth claimed that herd immunity from vaccines doesnt exist and provided four explanations for her claim. The post received over 7,000 likes and 200 comments as of 30 April 2021. As we demonstrate below, this claim is inaccurate, as are all four explanations given by Elizabeth.

Figure Screenshot of Laura Elizabeths post about vaccine herd immunity. On the left is her claim, and on the right are the four inaccurate reasons to explain her claim.

Elizabeth claimed that 100 percent of the population would have to be vaccinated to achieve herd immunity. However, in several cases, herd immunity can be achieved even when less than 100% of the population is vaccinated. The more infectious a disease is, the higher the proportion of the population that has to be protected before we get to herd immunity, explained epidemiologist Gypsyamber DSouza, a professor at the Johns Hopkins Bloomberg School of Public Health, in a video released by Johns Hopkins.

For a highly infectious disease like measles, where each infected person on average transmits the virus to between 12 to 18 other individuals, at least 95% of the population must be vaccinated to achieve herd immunity. For a less infectious disease like polio, the necessary threshold of vaccinated individuals is about 80%. The vaccine threshold for COVID-19 is still a matter of debate, but recent estimates range from 70 to 90 percent.

In short, herd immunity requires that a sufficiently high percentage of the population be protected, so that it is difficult for the infectious disease to spread through the population. But that percentage varies greatly depending on the characteristics of the disease, especially how infectious it is. Hence, Elizabeths claim that 100 percent of the population would have to be vaccinated for herd immunity to be achieved is inaccurate.

The immune system is a complex network of cells, tissues, organs, and the substances they make that helps the body fight infections and other diseases, according to the U.S. National Cancer Institute. When a persons immune system recognizes an invading pathogen for the first time, the system begins to address the problem. White blood cells converge on the site of the infection, while antibodies that specifically target that pathogen are produced. It can take several days for antibodies to develop and, in the meantime, the infected individual may become ill. Following this first exposure, however, the immune system will remember this pathogen and more quickly mount an immune response when it encounters the pathogen again.

Vaccines work by providing a persons immune system with a sneak peek of a pathogen. This sneak peek involves a weakened or inactive part of the pathogen, which allows the vaccinated persons immune system to create antibodies against the pathogen and avoid the risks of an actual infection. When an individual is exposed to a pathogen theyre vaccinated for, their immune system can quickly respond to it.

In her Instagram post, Elizabeth claimed that vaccines dont promise immunity. That is inaccurate. Immunity is the ability of the body to resist a particular disease, and that is exactly what vaccines are designed to provide. By giving a sneak peek of a pathogen, vaccines allow an individual to swiftly mount an immune response when they encounter the pathogen in the future.

Elizabeth also inaccurately claims that a great deal of people dont become immune after getting the vaccine. No vaccine is 100% effective, which is why some individuals may still get infected after theyve been vaccinated. But the percentage of individuals who do not generate immunity following vaccination is small. For instance, about one percent of people who receive both doses of the Measles, Mumps, Rubella (MMR) vaccine dont develop protective immunity.

In her post, Elizabeth claimed that immunity from vaccines is temporary. This is inaccurate because the duration of immunity generated by both vaccines and natural infection varies for different pathogens. For instance, people who receive two doses of the MMR vaccine are considered to have lifelong immunity for both measles and rubella. However, immunity to mumps decreases over time, which is why the CDC recommends a booster shot of the MMR vaccine during mumps outbreaks. In general, vaccine boosters are recommended because of waning immunity.

Elizabeth also implied that natural immunity is lifelong and therefore superior to vaccine immunity. This isnt the case, because infection with the pathogen can generate a dramatic range of immune responses. In the case of COVID-19, for instance, as many as 9% of recovered people have no detectable antibodies, although many who survive the disease develop immunity that may persist for years. Furthermore, those with a mild illness from COVID-19 may see their immunity wane after a few months.

One possible reason for individual variation in immunity following infection is that individuals are exposed to different amounts of the virus. With vaccines, however, everyone receives a similar dose that is known to be effective at generating an immune response. In a piece for The Conversation, immunologist Jennifer Grier, an assistant professor at the University of South Carolina, explained that COVID19 vaccines offer safer and more reliable immunity than natural infection, because immunity following natural infection can be unpredictable. As detailed in a previous Health Feedback review, vaccines also allow individuals to gain immunity without the risks associated with natural infection.

There are a few vaccine technologies that are commonly used. The classical types are inactivated, live-attenuated, and subunit vaccine designs. With the COVID-19 vaccines, two new designs have been added to the repertoire: mRNA and viral vector vaccines.

Inactivated vaccines use a killed version of the pathogen to confer immunity. Examples of inactivated vaccines include the flu, polio, Hepatitis A and rabies vaccines. Live-attenuated vaccines use an attenuated or weakened version of the pathogen, which is unable to cause disease, to generate immunity. Examples of live-attenuated vaccines include the MMR, rotavirus, smallpox, chickenpox and yellow fever vaccines.

Subunit vaccines use only a component from the pathogen, like a protein, to confer immunity. The Hepatitis B, human papillomavirus, whooping cough, pneumococcal, meningococcal, and shingles vaccines are examples of subunit vaccines.

Among the COVID-19 vaccines are mRNA and viral vector vaccines, two designs that deliver information to cells on how to produce a pathogens protein. These proteins then trigger the immune response, generating immunity.

In her post, Elizabeth claimed that all live virus vaccines shed. Vaccine shedding is the idea that vaccinated individuals will release or shed viruses into the population. Because most vaccine design strategies use a killed pathogen or only part of a pathogen, none of these types of vaccines can lead to vaccine shedding. In her post, Elizabeth writes that the shingles vaccine sheds, however, the shingles vaccine is a subunit vaccine and cant cause vaccine shedding.

Because they contain a weakened version of the pathogen, live-attenuated vaccines have the potential to shed live viruses. However, whats being shed is the weakened version of the pathogen used in the vaccine, which doesnt make people sick. One example of a vaccine that causes shedding is the smallpox vaccine, which helped eradicate the disease and is no longer routinely administered. For this vaccine, shedding could happen at the site of injection up to 19 days. The oral poliovirus (OPV) vaccine also leads to shedding of the weakened poliovirus in up to 90% of infants [1]. Some countries have swapped the OPV for the inactivated poliovirus (IPV) vaccine, which doesnt shed, because in rare occasions the shed vaccine virus may mutate and cause polio.

Of the routine vaccines given, both the rotavirus and chickenpox vaccines do shed, but in both cases infection is unlikely. For rotavirus, the vaccinevirus is shed in the stool and proper hygiene, such as hand washing, can prevent infection. In the case of the chickenpox vaccine, some people develop a rash after vaccination and the vaccine virus can shed from the rash. If this happens, individuals who arent immunocompetent or not yet vaccinated should stay away from the vaccinated individual until the rash is gone.

As such, though live virus vaccines can shed, the risk of infecting others is low because its the weakened version of the virus that is shed and individuals can take additional precautions to prevent infection. As such, Elizabeths claim that all live virus vaccines shed is misleading because it doesnt provide a complete picture of vaccine shedding. Particularly, it fails to mention that what is shed is the weakened version of the virus.

Herd immunity is achieved when the majority of a population is immune to a pathogen; this makes it hard for the pathogen to circulate in the population, which indirectly provides protection to the minority of individuals who arent immune. The safest way to achieve herd immunity is to vaccinate a very large percentage of the population. The World Health Organization has spoken against strategies that aim to achieve herd immunity through natural infection, since this would result in unnecessary cases and deaths. Therefore, claims that vaccines dont provide immunity and therefore cannot lead to herd immunity are inaccurate.

Visit link:
Vaccines do provide immunity and can be used to achieve herd immunity - Health Feedback

Read More...

NIH to study COVID-19 vaccine effectiveness on patients with compromised immune systems – FOX 5 NY

May 2nd, 2021 1:53 am

Vaccine expert on differences between Johnson & Johnson and Pfizer, Moderna

Dr. Williams Moss, an epidemiologist and executive director of the International Vaccine Access Center at Johns Hopkins, shares the science behind adenovirus vs. mRNA vaccines.

BETHESDA, Md. - The National Institutes of Health announced on April 23, that it is launching a study to assess how people with compromised immune systems respond to COVID-19 vaccines.

The study has already begun enrolling participants at the National Institutes of Health Clinical Center in Bethesda, Maryland, the NIH said. It will be a single-site study with up to 500 people enrolled, 400 of whom will have primary or secondary immune system disorders and 100 without such conditions.

The study will be led by researchers at NIHs National Institute of Allergy and Infectious Diseases (NIAID).

Dr. Anthony Fauci, the nations leading expert on infectious diseases and the director of NIAID said, "Through large Phase 3 trials, several experimental COVID-19 vaccines were shown to be safe and effective and three are now authorized by the U.S. Food and Drug Administration for emergency use in the United States."

Dr. Ziyad Al-Aly from the St. Louis VA Healthcare System talks about a study that found an increased risk of death in patients who developed so-called 'long COVID.'

"People with immune disorders are typically excluded from trials of experimental vaccines, and this was the case in the COVID-19 vaccine trials. This new study will characterize the features and adequacy of immune responses to COVID-19 vaccination in people with a range of immune deficiencies and dysregulation syndromes and will provide valuable information about benefits and potential risks in these individuals," Fauci continued.

Previous research has raised questions about how well COVID-19 vaccines protect people with compromised immune systems.

RELATED: Vice President Harris tells UN it's time now to prepare for next pandemic

A study published on March 15 by researchers at Johns Hopkins University looked at how COVID-19 vaccines specifically protected organ transplant recipients. Transplant recipients take powerful immune-suppressing drugs to prevent organ rejection, which also increases their risk from the coronavirus.

Vaccines rev up the immune system to recognize the virus, something thats harder to do if someones immune cells arent in good working order.

For the Johns Hopkins study, researchers tested 436 people who had received new organs in recent years and were getting the Pfizer or Moderna vaccines. A few weeks after the first dose, 17% of the transplant recipients had developed antibodies against the coronavirus, said Dr. Dorry Segev, a Hopkins transplant surgeon who co-authored the study.

Of most concern were people whose transplant medications included a type called an anti-metabolite. They were far less likely to respond to the shot than those who dont require that kind of drug, the study in the Journal of the American Medical Association said.

RELATED:Activities you can safely do once fully vaccinated against COVID-19

The findings came after the U.S. Centers for Disease Control and Prevention said fully vaccinated people can relax some, but not all, of the masking and distancing precautions against the coronavirus.

Dr. David Mulligan, Yale Universitys chief of transplant surgery and immunology, said the study was a disappointment but not a surprise because people with weak immune systems dont respond as well to other vaccines.

Some transplant groups, including the American Society of Transplantation, already have issued cautions about that.

As for the most recent NIH study, scientists say they hope to better understand how people with immune deficiencies respond to COVID-19 vaccines.

"Currently, there are few published studies on the incidence and clinical presentation of COVID-19 disease in people who have immune deficiencies, especially those who have inborn conditions involving deficits or dysregulations in antibody or cell-based immune responses to infections," said study principal investigator Emily Ricotta, Ph.D., MSc, of the NIAID Laboratory of Clinical Immunology and Microbiology. "Our study aims to fill this knowledge gap."

This story was reported from Los Angeles. The Associated Press contributed.

View original post here:
NIH to study COVID-19 vaccine effectiveness on patients with compromised immune systems - FOX 5 NY

Read More...

FACTCHECK COLUMN: Vaccines benefit those who have had COVID-19 – Montrose Daily Press

May 2nd, 2021 1:53 am

The authorized COVID-19 vaccines have been found to be safe and effective in clinical trials and in real-world conditions. Out of more than220 million doses administered so farand clinical trials with thousands of participants, there is no evidence showing that vaccinating those with previous SARS-CoV-2 infections could beunsafe.

On the contrary,increasinglygrowingevidenceshowsonedoseofthevaccine benefits individuals whove recovered from the infection, boosting their immune response and providing them with full protection for a period of time.

Our study and several other studies show that there is a benefit, immunologically in people who were previously infected,E. John Wherry, director of the University of Pennsylvanias Institute for Immunology, told FactCheck.org in a phone interview.

Yet a number of viral postsquestionthe need of vaccinating those whove already recovered from COVID-19, andone of them, published by Robert F. Kennedy Jr.s anti-vaccination organization, falsely claims it could potentially cause harm, or even death.

Researchers told FactCheck.org that is not what the evidence is showing.

Theres no indication that vaccinating people who had previously had COVID is resulting in an increased risk of adverse events, Wherry said.

Wherry, who is one of the lead authors of astudylooking at the immune responses to the mRNA vaccines in individuals with and without previous infections, said people who recover from the disease show different levels of antibodies created by the immune system to identify and neutralize the virus. The vaccines, he said, improved the immunity response in individuals by raising the levels of neutralizing antibodies in those whove been infected.

Some people actually have fairly low antibody responses that are not sufficient to neutralize the virus, especially variant viruses. When you vaccinate them uniformly, you get high antibody titers [measurements] and high neutralization titers, so theres an improvement in at least one of the key metrics of immunity following vaccination, he said.

According to guidance by the Centers for Disease Control and Prevention, people whove already had COVID-19should be vaccinated anywaybecause experts do not yet know how long they are protected from getting sick again. Those whove gotten the disease get some protection by building whats called natural immunity. And although available evidence shows that reinfection is uncommon in the months following the first infection, theCDC saysthat may vary over time.

Available data suggest that previously infected individuals can be at risk of COVID-19 (i.e., reinfection) and could benefit from vaccination. Furthermore, data suggest that the safety profile of COVID-19 vaccines in previously infected individuals is just as favorable as in previously uninfected individuals, a spokesperson for the U.S. Food and Drug Administration told us in an email.

Up until now, the passive and activesurveillance systemsset up to monitor the safety of the COVID-19 vaccines have only foundrare adverse eventsassociated with the vaccines.

A small number of people (2 to 5 people per million vaccinated) have reported a severe allergic reaction called anaphylaxis. And the CDC and the FDA are studyinga small number of casesof people who experienced arare and severetype of blood clot with low platelets after getting the Johnson & Johnson vaccine. As a result, theagencies recommended a pausein the use of this product. On April 23, a CDC panel of advisersrecommended the pause be lifted.

No evidence of risk for previously infected individuals

Ina blog poston The Defender, a website owned by R.F.K. Jr.s organization, Childrens Health Defense, a freelance reporter writes that theres no science supporting the need of vaccinating people who have recovered from COVID-19. Theres a potential risk of harm, including death, in vaccinating those whove already had the disease or were recently infected, the post claimed.

Researchers dont agree, including one quoted by The Defender.

Dr. Colleen Kelley, an associate professor of medicine and epidemiology at Emory University School of Medicine andthe principal investigator for Modernas and Novavaxs phase 3 vaccine trials at Emory, is quoted by The Defender as saying people with previous infection get harsher side effects after vaccination. Her remarks came from aHuffPostarticle in March.

In a phone interview, Kelley told us that tolerable side effects are expected, and not always present. In the Moderna trials, there did not appear to be an increased rate of side effects among people who were antibody positive when they were vaccinated, she said.

There is absolutely no evidence that there is any harm for people to be vaccinated, who have previously had COVID disease,Kelley said.

The Defenders claims are mostly based on statements by Dr. Hooman Noorchashm, a formerassistant professor of surgeryat the University of Pennsylvania School of Medicine, who has beenwarning health officials, vaccine manufacturers and more recently university leadersof the potential danger of vaccinating people who have recently been infected with the novel coronavirus.

Noorchashm has been voicing his arguments widely, including on Fox News Tucker Carlson TodayandThe Defender podcast.But headmitsthey are based on a prognostication in that I have put it forth in the absence of clear evidence of it being a material risk.

Based on previous studies not related to the COVID-19 pandemic, Noorchashm argues that antigens of SARS-CoV-2 remain in the tissues of someone whos been infected for some time after theyve recovered. The vaccine, he says, reactivates the immune response, targeting the tissues where these antigens remain, causing further inflammation and damage, including to the vascularendothelium,the thin tissue that lines the heart and blood vessels.

Most pertinently, when viral antigens are present in the vascular endothelium or other layers of the blood vessel, and especially in elderly and frail with cardiovascular disease, the antigen specific immune response incited by the vaccine is almost certain to do damage to the vascular endothelium, he said in a Jan. 26lettersent to FDA officials and Pfizer executives. Such vaccine directed endothelial damage is certain to cause blood clot formation with the potential for major thromboembolic complications, at least in a subset of such patients.

In a phone interview with FactCheck.org, Noorchashm explained that all medical treatments, including vaccines, have some complications. And if those complications happen when a treatment is avoidable in this case, he says, vaccinating those whove recently been infected then thats potentially harmful.

His recommendation is to test peoples antibodies before vaccination and to delay vaccination for approximately eight months after infection. He and his wife, aphysician who died in 2017,fought for yearsto ban a tool used to remove uterine fibroids, after the procedure spread cancer into his wifes abdomen.

Dr. Steven Varga, a professor of microbiology and immunology at the University of Iowa whose lab studies immunopathology in respiratory virus infections, told us hes not aware of any scientific data that demonstrates that viral antigens persist long after the SARS-CoV-2 infection has gone away. And if there were, he says, there would likely be insufficient levels to drive such a robust immune response to cause the damage Noorchashm suggests.

Generally, once the virus is cleared, there can be some viral antigen that persists in various locations, so it is possible there could be some in the endothelium, Varga said. Again, Im not aware of any studies that have shown that to be the case. But even if there were small amounts of viral antigen, generally that shouldnt be enough viral antigen to induce the type of damage that would need to occur to have the kind of more severe outcome.

Dr. Donna Farber, a professor of microbiology and immunology at Columbia University focused on immunological memory, told us Noorchashms prognostication is not consistent with the data.

The data are that the virus is cleared from the lungs, the virus is cleared from the upper respiratory tract. And so if theres no virus, theres no antigen, Farber, who recently published astudy on the immune response to COVID-19 in the lungs, said in a phone interview.

Farber added that the protective immunity provided by the vaccine, neutralizing antibodies, do not cause the sort of harm Noorchashm is talking about. That could happen, she says as an example, if there was a virus hidden in cells and then a patient is given cytotoxic T cells,a type of immune cell that can kill infected cells or cancer cells.

But the chance of that happening in a vaccine and for a vaccine thats really targeting neutralizing antibodies and not, you know, the sort of a killer T cell response its just inconsistent with the science, she said.

Farber also said for most pathogens, our immune system requires repeated exposure to get protection over time. Thats why people get a vaccine for influenza every year, she said, regardless if theyve been exposed to the virus or not.

Seeing an antigen again and again, isnt bad for you. Its what we do all the time. And its what our immune system has evolved to do. And thats how it generates its best memory, she said.

This column was edited for space. See the whole column at FactCheck.org

Clarification, April 27: Although nothing in the article indicates that Dr. Noorchashm is a member of an anti-vaccination group, Dr. Noorchashm requested FactCheck to add that he is not anti-vaccine. He said he has been vaccinated against COVID-19.

SciChecks COVID-19/Vaccination Projectis made possible by a grant from the Robert Wood Johnson Foundation. The foundation hasno controlover our editorial decisions, and the views expressed in our articles do not necessarily reflect the views of the foundation. The goal of the project is to increase exposure to accurate information about COVID-19 and vaccines, while decreasing the impact of misinformation.

Original post:
FACTCHECK COLUMN: Vaccines benefit those who have had COVID-19 - Montrose Daily Press

Read More...

The future of animal nutrition includes clean feed – The Pig Site

May 2nd, 2021 1:53 am

When talking about clean feed, one of the most important topics is gut health. A healthy gut can lead to healthier animals, and ultimately, an improved return on investment (ROI).

Clean feed is a major factor influencing the development of a healthy gut in young animals. Low-quality feed ingredients promote inflammation through pro-inflammatory cytokines and the proliferation of pathogenic bacteria leading to nutritional disorders, negatively impacting growth.

Many feed ingredients contain anti-nutritional factors (ANF) like non-starch polysaccharides, beta-conglycinin, high aromatic amino acids, oxidized lipids, and gluten prolamins, all of which promote gut inflammation. In response to gut inflammation, expression of pro-inflammatory cytokines increases followed by an oxidative stress response which leads to increased apoptosis and further upregulation of pro-inflammatory cytokines. If the response to inflammatory compounds in feed ingredients continues, the vicious circle will continue as well, leading to chronic inflammation, lowering ROI.

The gut microbiome is heavily influenced by the composition of feed consumed by young animals. Feed ingredients can promote the proliferation of symbiotic bacteria or pathogenic bacteria. Feed ingredients containing ANFs will shift the gut microbiome from symbiotic to pathogenic bacteria, promoting infectious inflammations. By shifting the microbiome towards pathogenic bacteria and continuing to feed ingredients with ANFs, it allows for bacterial fermentation which can increase the risk of diarrhea and nutrition-related diseases.

An example of an ANF are trypsin inhibitors (TI) in soybean meal (SBM). High TI are one of the greatest factors decreasing the quality of SBM fed to monogastric animals, subsequently impacting feed digestibility and increasing gut inflammation. When pigs were fed a diet of 38% SBM with 8.78 mg/g of TI, amino acid digestibility decreased by 13-26% while digestibility of crude protein was reduced by 23.3% (Chen et al., 2020). A similar trend has been shown in broiler chickens in which high TI reduces protein digestibility, decreasing body weight gain and increasing feed conversion ratio (FCR) (Rada et al., 2017).

This is true in the case of ruminants, as well. One of the leading causes of calf death is enteric infection. Improving calf gut health mitigates the risk of developing enteric infections while improving the immune system and overall health of the animals. There is also evidence to suggest that alteration of the microbiome at a young age leads to improved milk production (Steele et al., 2016; Dill-McFarland et al., 2017).

Evidently, keeping it simple with the use of clean ingredients promotes the development of a healthy gut leading to many additional benefits like reduced intervention and a greater return on investment. This is important for setting young animals up for success from the start, supporting their long-term health and performance.

Ensuring gut health through clean feed ingredients can lead to improvements in overall health, reducing the need for intervention through management practices. Establishing a healthy gut through clean feed decreases the incidence of diarrhea, reduces oxidative stress, and can diminish the need for antibiotics. Responses to these forms of stress also require a great deal of energy to activate the immune response. This results in energy from the feed being put towards the immune response, rather than towards growth. Feeding clean feed ingredients support health while fostering perfect growing conditions.

Enhancing immunity and overall health of young animals can translate to an improved return on investment (ROI). Feeding ingredients with lower ANF early on in life reduces gut inflammation and oxidative stress while supporting development of a healthy immune system and leading to lower FCRs and therefore higher ROI. A reduced need for management interventions can also reduce the cost of production as less labor is needed and less will be spent on antibiotics/AGPs or other medications. While AGPs are forbidden in Europe, they are still used around the world, but with clean diets AGPs become redundant and unnecessary, further improving ROI. Clean feed creates value both in terms of animal health and financials.

Hamlet Protein produces clean soy-based feed ingredients for young animals with significantly lower ANFs compared to conventional SBM. The patented production process is gentle and uses an enzymatic treatment to reduce the levels of the most harmful ANFs without damaging the protein or the amino acids. The process is monitored very closely, making sure customers receive the exact same high quality every time.

Feeding Hamlet Protein products in the starter diet of young animals has been shown to enhance nutrient absorption, increase body weight gain, decrease FCR, all while reducing the incidence of metabolic disease and need for treatment. The Hamlet Protein difference is providing young animal feed ingredients that aid in establishing a healthy gut to enhance performance and, ultimately, increase ROI.

Here is the original post:
The future of animal nutrition includes clean feed - The Pig Site

Read More...

IBD treatment blunts immune response to Covid-19 vaccines – iNews

May 2nd, 2021 1:53 am

A common treatment for inflammatory bowel disease (IBD) blunts the immune response to a Covid-19 vaccine, a study has found.

Exeter University researchers measured antibody responses after vaccination with the Pfizer/BioNTech or the Oxford/AstraZeneca vaccine in 865 people treated with infliximab, an anti-tumour necrosis factor (anti-TNF) biologic drug, prescribed to around two million people worldwide.

Anti-TNF drugs are effective treatments for immune-mediated inflammatory diseases, but by suppressing the immune system, they can reduce vaccine effectiveness and increase risk of serious infection.

The freshest exclusives and sharpest analysis, curated for your inbox

IBD is a term mainly used to describe two conditions, ulcerative colitis and Crohns disease, both long-term conditions that involve inflammation of the gut. It affects at least one in 250 people of the UK population and the prevalence is rising.

The Exeter team found that people treated with infliximab had significantly lower concentrations of antibodies, when compared to 428 people on an alternative treatment, vedolizumab.

After a single dose of vaccine, only about one third of participants (103 of 328) treated exclusively with infliximab generated adequate levels of antibodies to the virus for the vaccine to be considered effective.

In participants simultaneously taking infliximab and immunomodulator drugs, such as azathioprine or methotrexate, the levels of antibodies were even lower after a single vaccine dose; only 125 of 537 met the threshold of a positive antibody test.

However, in a sub-group of people who had previously been infected with Covid-19, and also in the few patients studied who had already had a second dose of vaccine, the vaccine-triggered antibody responses rose significantly, indicating an effective response after two exposures.

Based on these observations, the researchers conclude that people taking anti-TNF drugs should be considered a priority for a second vaccination.

Co-author Dr Nick Powell, of Imperial College London, said: Although we know that this has been an incredibly difficult time for people with IBD, our research indicates that people treated with infliximab should consider that they are not protected from Covid-19 until they have had both doses of a vaccine and should continue to practice enhanced physical distancing and shielding if appropriate.

The study is published in the journal Gut.

Read more here:
IBD treatment blunts immune response to Covid-19 vaccines - iNews

Read More...

Page 224«..1020..223224225226..230240..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick